Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
The latest announcement is out from ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H ( (HK:1541) ).
ImmuneOnco Biopharmaceuticals announced the disposal of a subsidiary, where the purchase price was determined through arm’s length negotiations and an asset-based valuation. This decision reflects the company’s strategic move to focus on its core operations and could impact its financial positioning as it divests from non-essential assets.
More about ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H
ImmuneOnco Biopharmaceuticals (Shanghai) Inc is a company incorporated in the People’s Republic of China, primarily focused on the biopharmaceutical industry. It engages in the development of innovative cancer immunotherapies, aiming to address unmet medical needs and improve patient outcomes.
YTD Price Performance: -2.33%
Average Trading Volume: 13,456,896
Technical Sentiment Consensus Rating: Buy
Current Market Cap: HK$2.05B
Learn more about 1541 stock on TipRanks’ Stock Analysis page.
